-
1
-
-
9044254525
-
P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
-
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
-
(1996)
Pharmacogenetics
, vol.6
, pp. 1-42
-
-
Nelson, D.R.1
Koymans, L.2
Kamataki, T.3
Stegeman, J.J.4
Feyereisen, R.5
Waxman, D.J.6
-
2
-
-
0035135258
-
cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450
-
Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol 2001; 59: 386-92.
-
(2001)
Mol Pharmacol
, vol.59
, pp. 386-392
-
-
Domanski, T.L.1
Finta, C.2
Halpert, J.R.3
Zaphiropoulos, P.G.4
-
3
-
-
0028237729
-
Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
-
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengench FP. Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23.
-
(1994)
J Pharmacol Exp Ther
, vol.270
, pp. 414-423
-
-
Shimada, T.1
Yamazaki, H.2
Mimura, M.3
Inui, Y.4
Guengench, F.P.5
-
4
-
-
0030834058
-
Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
-
Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug. Metab Rev 1997; 29: 413-580.
-
Drug. Metab Rev 1997
-
-
Rendic, S.1
Di Carlo, F.J.2
-
5
-
-
0028114619
-
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
-
Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271: 549-56.
-
(1994)
J Pharmacol Exp Ther
, vol.271
, pp. 549-556
-
-
Thummel, K.E.1
Shen, D.D.2
Podoll, T.D.3
Kunze, K.L.4
Trager, W.F.5
Hartwell, P.S.6
-
6
-
-
2342448026
-
Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver
-
Watanabe M, Kumai T, Matsumoto N, Tanaka M, Suzuki S, Satoh T, et al. Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver. J Pharmacol Sci 2004; 94: 459-62.
-
(2004)
J Pharmacol Sci
, vol.94
, pp. 459-462
-
-
Watanabe, M.1
Kumai, T.2
Matsumoto, N.3
Tanaka, M.4
Suzuki, S.5
Satoh, T.6
-
7
-
-
1542376174
-
Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens
-
von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-83.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 172-183
-
-
von Richter, O.1
Burk, O.2
Fromm, M.F.3
Thon, K.P.4
Eichelbaum, M.5
Kivisto, K.T.6
-
8
-
-
0036515846
-
Receptor-dependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man
-
Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32: 165-206.
-
(2002)
Xenobiotica
, vol.32
, pp. 165-206
-
-
Gibson, G.G.1
Plant, N.J.2
Swales, K.E.3
Ayrton, A.4
El-Sankary, W.5
-
9
-
-
0036223831
-
Summary of information on human CYP enzymes: Human P450 metabolism data
-
Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448.
-
(2002)
Drug Metab Rev
, vol.34
, pp. 83-448
-
-
Rendic, S.1
-
10
-
-
0032924934
-
Cytochrome P-450 3A4: Regulation and role in drug metabolism
-
Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17.
-
(1999)
Annu Rev Pharmacol Toxicol
, vol.39
, pp. 1-17
-
-
Guengerich, F.P.1
-
11
-
-
16444377083
-
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs
-
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 279-304
-
-
Zhou, S.1
Yung Chan, S.2
Cher Goh, B.3
Chan, E.4
Duan, W.5
Huang, M.6
-
12
-
-
4644308675
-
-
Zhou SF, Chan E, Lim LY, Boelsterli UA, Li SC, Wang JC, et al. Curr Drug Metab 2004; 5: 415-42.
-
(2004)
Curr Drug Metab
, vol.5
, pp. 415-442
-
-
Zhou, S.F.1
Chan, E.2
Lim, L.Y.3
Boelsterli, U.A.4
Li, S.C.5
Wang, J.C.6
-
13
-
-
0031819080
-
Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A
-
Voorman RL, Maio SK Hauer MJ, Sanders PE, Payne NA, Ackland MJ. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 1998; 26: 631-9.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 631-639
-
-
Voorman, R.L.1
Maio, S.K.2
Hauer, M.J.3
Sanders, P.E.4
Payne, N.A.5
Ackland, M.J.6
-
14
-
-
0034681931
-
Mechanism-based inactivation of cytochrome P450 3A4 by L-754.394
-
Lightning LK, Jones JP, Friedberg T, Pritchard MP, Shou M, Rushmore TK et al. Mechanism-based inactivation of cytochrome P450 3A4 by L-754.394. Biochemistry 2000; 39: 4276-87.
-
(2000)
Biochemistry
, vol.39
, pp. 4276-4287
-
-
Lightning, L.K.1
Jones, J.P.2
Friedberg, T.3
Pritchard, M.P.4
Shou, M.5
Rushmore, T.K.6
-
15
-
-
0036196318
-
Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: Evidence for heme destruction and covalent binding to protein
-
Lin HL, Kent UM, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: Evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther 2002; 301: 160-7.
-
(2002)
J Pharmacol Exp Ther
, vol.301
, pp. 160-167
-
-
Lin, H.L.1
Kent, U.M.2
Hollenberg, P.F.3
-
16
-
-
0036178095
-
Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation
-
Khan KK, He YQ, Domanski TL, Halpert JR. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: An evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 2002; 61: 495-506.
-
(2002)
Mol Pharmacol
, vol.61
, pp. 495-506
-
-
Khan, K.K.1
He, Y.Q.2
Domanski, T.L.3
Halpert, J.R.4
-
17
-
-
27244462157
-
Covalent alteration of the CYP3A4 active site: Evidence for multiple substrate binding domains
-
Schrag ML, Wienkers LC. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 2001; 391: 49-55.
-
(2001)
Arch Biochem Biophys
, vol.391
, pp. 49-55
-
-
Schrag, M.L.1
Wienkers, L.C.2
-
18
-
-
0026346377
-
Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds
-
Franklin MR. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 1991; 206: 559-73.
-
(1991)
Methods Enzymol
, vol.206
, pp. 559-573
-
-
Franklin, M.R.1
-
19
-
-
0036259952
-
The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9
-
Kent UM, Aviram M, Rosenblat M, Hollenberg PF. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 2002; 30: 709-15.
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 709-715
-
-
Kent, U.M.1
Aviram, M.2
Rosenblat, M.3
Hollenberg, P.F.4
-
20
-
-
0344765487
-
Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate
-
Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26: 609-16.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 609-616
-
-
Lillibridge, J.H.1
Liang, B.H.2
Kerr, B.M.3
Webber, S.4
Quart, B.5
Shetty, B.V.6
-
21
-
-
44449085280
-
-
Ortiz de Montellano PR, Correia MA. In Cytochrome P450: Structure, Mechanism and Biochemistry, PR Ortiz de Montellano, ed.; Plenum Press: New York, 1995; pp. 305-66.
-
Ortiz de Montellano PR, Correia MA. In Cytochrome P450: Structure, Mechanism and Biochemistry, PR Ortiz de Montellano, ed.; Plenum Press: New York, 1995; pp. 305-66.
-
-
-
-
23
-
-
0029807226
-
Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine
-
Laganière S, Davies RF, Carignan G, Foris K, Goemert L, Carrier K, et al. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther 1996; 60: 255-64.
-
(1996)
Clin Pharmacol Ther
, vol.60
, pp. 255-264
-
-
Laganière, S.1
Davies, R.F.2
Carignan, G.3
Foris, K.4
Goemert, L.5
Carrier, K.6
-
24
-
-
0028359701
-
Dose of midazolam should be reduced during diltiazem and verapamil treatments
-
Backman JT, Olkkola KT, Aranko Y, Himberg J-J, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221-5.
-
(1994)
Br J Clin Pharmacol
, vol.37
, pp. 221-225
-
-
Backman, J.T.1
Olkkola, K.T.2
Aranko, Y.3
Himberg, J.-J.4
Neuvonen, P.J.5
-
25
-
-
0023896584
-
-
Toyosaki N, Toyo-Oka T, Natsume T, Katsuki TA, Tateishi T, Yaginuma T, et al. Circulation 1988; 77: 1370-5.
-
(1988)
Circulation
, vol.77
, pp. 1370-1375
-
-
Toyosaki, N.1
Toyo-Oka, T.2
Natsume, T.3
Katsuki, T.A.4
Tateishi, T.5
Yaginuma, T.6
-
26
-
-
0031718706
-
The interaction of diltiazem with lovastatin and pravastatin
-
Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369-77.
-
(1998)
Clin Pharmacol Ther
, vol.64
, pp. 369-377
-
-
Azie, N.E.1
Brater, D.C.2
Becker, P.A.3
Jones, D.R.4
Hall, S.D.5
-
27
-
-
4644308675
-
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4
-
Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004; 5: 415-42.
-
(2004)
Curr Drug Metab
, vol.5
, pp. 415-442
-
-
Zhou, S.1
Chan, E.2
Lim, L.Y.3
Boelsterli, U.A.4
Li, S.C.5
Wang, J.6
-
28
-
-
0025236599
-
Metabolite inhibition of parent drug biotransformation. Studies of diltiazem
-
Tsao S-C, Dickinson TH, Abernethy DR. Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. Drug Metab Dispos 1990; 18: 180-2.
-
(1990)
Drug Metab Dispos
, vol.18
, pp. 180-182
-
-
Tsao, S.-C.1
Dickinson, T.H.2
Abernethy, D.R.3
-
30
-
-
0032496879
-
-
Mullins ME, Horowitz Z, Linden DHJ, Smith GW, Norton RL, Stump J. JAMA 1998; 280: 157-8.
-
(1998)
JAMA
, vol.280
, pp. 157-158
-
-
Mullins, M.E.1
Horowitz, Z.2
Linden, D.H.J.3
Smith, G.W.4
Norton, R.L.5
Stump, J.6
-
31
-
-
0033026601
-
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
-
Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, et al. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations. Br J Clin Pharmacol 1999; 47: 291-8.
-
(1999)
Br J Clin Pharmacol
, vol.47
, pp. 291-298
-
-
Prueksaritanont, T.1
Ma, B.2
Tang, C.3
Meng, Y.4
Assang, C.5
Lu, P.6
-
32
-
-
0033972441
-
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
-
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
-
(2000)
Clin Pharmacokinet
, vol.38
, pp. 41-57
-
-
Dresser, G.K.1
Spence, J.D.2
Bailey, D.G.3
-
34
-
-
0033924849
-
Drug interactions with cisapride: Clinical implications
-
Michalets EL, Williams CR. Drug interactions with cisapride: Clinical implications. Clin Pharmacokinet 2000; 39: 49-75.
-
(2000)
Clin Pharmacokinet
, vol.39
, pp. 49-75
-
-
Michalets, E.L.1
Williams, C.R.2
-
35
-
-
0026671408
-
Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
-
Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231-8.
-
(1992)
Clin Pharmacol Ther
, vol.52
, pp. 231-238
-
-
Honig, P.K.1
Woosley, R.L.2
Zamani, K.3
Conner, D.P.4
Cantilena, L.R.5
-
36
-
-
0027996327
-
Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals
-
Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22: 849-57.
-
(1994)
Drug Metab Dispos
, vol.22
, pp. 849-857
-
-
Jurima-Romet, M.1
Crawford, K.2
Cyr, T.3
Inaba, T.4
-
37
-
-
0027468346
-
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
-
Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-8.
-
(1993)
JAMA
, vol.269
, pp. 1513-1518
-
-
Honig, P.K.1
Wortham, D.C.2
Zamani, K.3
Conner, D.P.4
Mullin, J.C.5
Cantilena, L.R.6
-
38
-
-
0036291921
-
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
-
Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-70.
-
(2002)
Clin Pharmacokinet
, vol.41
, pp. 343-370
-
-
Williams, D.1
Feely, J.2
-
39
-
-
0034986591
-
Cardiovascular drug-drug interactions
-
Anderson JR, Nawarskas JJ. Cardiovascular drug-drug interactions. Cardiol Clin 2001; 19: 215-34.
-
(2001)
Cardiol Clin
, vol.19
, pp. 215-234
-
-
Anderson, J.R.1
Nawarskas, J.J.2
-
40
-
-
0036019860
-
Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease
-
Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int J Impot Res 2002; 14: 178-88.
-
(2002)
Int J Impot Res
, vol.14
, pp. 178-188
-
-
Simonsen, U.1
-
42
-
-
0029815563
-
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update
-
Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31: 198-214.
-
(1996)
Clin Pharmacokinet
, vol.31
, pp. 198-214
-
-
Spina, E.1
Pisani, F.2
Perucca, E.3
-
43
-
-
0029011397
-
The interaction of the calcium antagonist RO 40-5967 with digoxin
-
Siepmann M, Kleinbloesem C, Kirch W. The interaction of the calcium antagonist RO 40-5967 with digoxin. Br J Clin Pharmacol 1995; 39: 491-6.
-
(1995)
Br J Clin Pharmacol
, vol.39
, pp. 491-496
-
-
Siepmann, M.1
Kleinbloesem, C.2
Kirch, W.3
-
44
-
-
0034082667
-
Diltiazem and imbefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone
-
Varis T, Backman JT, Kivisto KT, Neuvonen PJ. Diltiazem and imbefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000; 67: 215-21.
-
(2000)
Clin Pharmacol Ther
, vol.67
, pp. 215-221
-
-
Varis, T.1
Backman, J.T.2
Kivisto, K.T.3
Neuvonen, P.J.4
-
46
-
-
0031802051
-
Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients
-
Spoendlin M, Peters J, Welker H, Bock A, Thiel G. Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol Dial Transplant 1998; 13: 1787-91.
-
(1998)
Nephrol Dial Transplant
, vol.13
, pp. 1787-1791
-
-
Spoendlin, M.1
Peters, J.2
Welker, H.3
Bock, A.4
Thiel, G.5
-
47
-
-
1542640490
-
Rhabdomyolysis due to interaction of simvastatin with mibefradil
-
Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351: 1929-30.
-
(1998)
Lancet
, vol.351
, pp. 1929-1930
-
-
Schmassmann-Suhijar, D.1
Bullingham, R.2
Gasser, R.3
Schmutz, J.4
Haefeli, W.E.5
-
49
-
-
0033977595
-
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: Linking in vitro with in vivo information
-
Muck W. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: Linking in vitro with in vivo information. Br J Clin Pharmacol 2000; 49: 87-90.
-
(2000)
Br J Clin Pharmacol
, vol.49
, pp. 87-90
-
-
Muck, W.1
-
50
-
-
0036251569
-
Hepatotoxicity of commonly used drugs: Nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs
-
Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-83.
-
(2002)
Semin Liver Dis
, vol.22
, pp. 169-183
-
-
Chitturi, S.1
George, J.2
-
51
-
-
0030927213
-
Protein targets of xenobiotic reactive intermediates
-
Pumford NR, Halmes NC. Protein targets of xenobiotic reactive intermediates. Annu Rev Pharmacol Toxicol 1997; 37: 91-117.
-
(1997)
Annu Rev Pharmacol Toxicol
, vol.37
, pp. 91-117
-
-
Pumford, N.R.1
Halmes, N.C.2
-
52
-
-
0037027003
-
Protein adducts: Quantitative and qualitative aspects of their formation, analysis and applications
-
Tornqvist M, Fred C, Haglund J, Helleberg H, Paulsson B, Rydberg P. Protein adducts: Quantitative and qualitative aspects of their formation, analysis and applications. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 778: 279-308.
-
(2002)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.778
, pp. 279-308
-
-
Tornqvist, M.1
Fred, C.2
Haglund, J.3
Helleberg, H.4
Paulsson, B.5
Rydberg, P.6
-
53
-
-
0031106284
-
Selective protein covalent binding and target organ toxicity
-
Cohen SD, Pumford NR, Khairallah EA, Boekelheide K, Pohl LR, Amouzadeh HR, et al. Selective protein covalent binding and target organ toxicity. Toxicol Appl Pharmacol 1997; 143: 1-12.
-
(1997)
Toxicol Appl Pharmacol
, vol.143
, pp. 1-12
-
-
Cohen, S.D.1
Pumford, N.R.2
Khairallah, E.A.3
Boekelheide, K.4
Pohl, L.R.5
Amouzadeh, H.R.6
-
55
-
-
0035436665
-
Reactive metabolites and their role in drug reactions
-
Naisbitt DJ, Williams DP, Pirmohamed M, Kitteringham NR, Park BK. Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol 2001; 1: 317-25.
-
(2001)
Curr Opin Allergy Clin Immunol
, vol.1
, pp. 317-325
-
-
Naisbitt, D.J.1
Williams, D.P.2
Pirmohamed, M.3
Kitteringham, N.R.4
Park, B.K.5
-
56
-
-
0035996570
-
Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system
-
Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002; 3: 367-77.
-
(2002)
Curr Drug Metab
, vol.3
, pp. 367-377
-
-
Ju, C.1
Uetrecht, J.P.2
-
58
-
-
0036163759
-
Mechanisms of hepatotoxicity
-
Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-76.
-
(2002)
Toxicol Sci
, vol.65
, pp. 166-176
-
-
Jaeschke, H.1
Gores, G.J.2
Cederbaum, A.I.3
Hinson, J.A.4
Pessayre, D.5
Lemasters, J.J.6
-
59
-
-
0028071759
-
Noninvasive tests of CYP3A enzymes
-
Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-84.
-
(1994)
Pharmacogenetics
, vol.4
, pp. 171-184
-
-
Watkins, P.B.1
-
60
-
-
0037374331
-
Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity
-
Kharasch ED, Hoffer C, Walker A, Sheffels P. Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther 2003; 73: 199-208.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 199-208
-
-
Kharasch, E.D.1
Hoffer, C.2
Walker, A.3
Sheffels, P.4
-
61
-
-
0009750846
-
Comparative safety of the different macrolides
-
Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18: S71-6.
-
(2001)
Int J Antimicrob Agents
, vol.18
-
-
Rubinstein, E.1
-
62
-
-
0029130840
-
Macrolide antibacterials. Drug interactions of clinical significance
-
von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13: 105-22.
-
(1995)
Drug Saf
, vol.13
, pp. 105-122
-
-
von Rosensteil, N.A.1
Adam, D.2
-
63
-
-
0033831197
-
An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation
-
Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28: 1031-7.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 1031-1037
-
-
Mayhew, B.S.1
Jones, D.R.2
Hall, S.D.3
-
64
-
-
0026451267
-
Fluoxetine impairs clearance of alprazolam but not of clonazepam
-
Greenblatt DJ, Preskom SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52: 479-86.
-
(1992)
Clin Pharmacol Ther
, vol.52
, pp. 479-486
-
-
Greenblatt, D.J.1
Preskom, S.H.2
Cotreau, M.M.3
Horst, W.D.4
Harmatz, J.S.5
-
65
-
-
0042634397
-
Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine
-
Hall J, Naranjo CA, Sproule BA, Herrmann N. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. J Clin Psychopharmacol 2003; 23: 349-57.
-
(2003)
J Clin Psychopharmacol
, vol.23
, pp. 349-357
-
-
Hall, J.1
Naranjo, C.A.2
Sproule, B.A.3
Herrmann, N.4
-
66
-
-
0036222136
-
The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients
-
Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 2002; 35: 50-6.
-
(2002)
Pharmacopsychiatry
, vol.35
, pp. 50-56
-
-
Bondolfi, G.1
Eap, C.B.2
Bertschy, G.3
Zullino, D.4
Vermeulen, A.5
Baumann, P.6
-
67
-
-
0028303957
-
Treatment and prevention of tuberculosis in HIV-infected persons
-
Cohn DL. Treatment and prevention of tuberculosis in HIV-infected persons. Infect Dis Clin North Am 1994; 8: 399-412.
-
(1994)
Infect Dis Clin North Am
, vol.8
, pp. 399-412
-
-
Cohn, D.L.1
-
68
-
-
0032710353
-
Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis
-
Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS 1999; 13: 2069-74.
-
(1999)
AIDS
, vol.13
, pp. 2069-2074
-
-
Gourevitch, M.N.1
Hartel, D.2
Selwyn, P.A.3
Schoenbaum, E.E.4
Klein, R.S.5
-
69
-
-
0035712266
-
Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes
-
Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol 2002; 57: 799-804.
-
(2002)
Eur J Clin Pharmacol
, vol.57
, pp. 799-804
-
-
Wen, X.1
Wang, J.S.2
Neuvonen, P.J.3
Backman, J.T.4
-
70
-
-
0014310394
-
Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs
-
Kutt H, Verebely K, McDowell F. Inhibition of diphenylhydantoin metabolism in rats and in rat liver microsomes by antitubercular drugs. Neurology 1968; 18: 706-10.
-
(1968)
Neurology
, vol.18
, pp. 706-710
-
-
Kutt, H.1
Verebely, K.2
McDowell, F.3
-
71
-
-
0018374181
-
Clinical importance of the interaction of phenytoin and isoniazid: A report from the Boston Collaborative Drug Surveillance Program
-
Miller RR, Porter J, Greenblatt DJ. Clinical importance of the interaction of phenytoin and isoniazid: A report from the Boston Collaborative Drug Surveillance Program. Chest 1979; 75: 356-8.
-
(1979)
Chest
, vol.75
, pp. 356-358
-
-
Miller, R.R.1
Porter, J.2
Greenblatt, D.J.3
-
73
-
-
0025267150
-
-
Samigun, Mulyono, Santoso B. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. Br J Clin Pharmacol 1990; 29: 570-3.
-
Samigun, Mulyono, Santoso B. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators. Br J Clin Pharmacol 1990; 29: 570-3.
-
-
-
-
74
-
-
0031007978
-
-
Wiltshire HR, Sutton BG, Heeps M, Betty AM, Angus DW, Harris SR, et al. Xenobiotica 1997; 27: 557-71.
-
(1997)
Xenobiotica
, vol.27
, pp. 557-571
-
-
Wiltshire, H.R.1
Sutton, B.G.2
Heeps, M.3
Betty, A.M.4
Angus, D.W.5
Harris, S.R.6
-
75
-
-
0033863264
-
Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro
-
Wandel C, Kim RB, Guengerich FP, Wood AJJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 2000; 28: 895-8.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 895-898
-
-
Wandel, C.1
Kim, R.B.2
Guengerich, F.P.3
Wood, A.J.J.4
-
77
-
-
0027394348
-
Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
-
Brogden RN, Goa KL, Faulds D. Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993; 45: 384-409.
-
(1993)
Drugs
, vol.45
, pp. 384-409
-
-
Brogden, R.N.1
Goa, K.L.2
Faulds, D.3
-
78
-
-
0031947562
-
Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice
-
He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11: 252-9.
-
(1998)
Chem Res Toxicol
, vol.11
, pp. 252-259
-
-
He, K.1
Iyer, K.R.2
Hayes, R.N.3
Sinz, M.W.4
Woolf, T.F.5
Hollenberg, P.F.6
-
79
-
-
0033061072
-
Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)
-
He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 1999; 288: 791-7.
-
(1999)
J Pharmacol Exp Ther
, vol.288
, pp. 791-797
-
-
He, K.1
Woolf, T.F.2
Hollenberg, P.F.3
-
80
-
-
0031931151
-
Antiprogestin-mediated inactivation of cytochrome P450 3A4
-
Jang GR, Benet LZ. Antiprogestin-mediated inactivation of cytochrome P450 3A4. Pharmacology 1998; 56: 150-7.
-
(1998)
Pharmacology
, vol.56
, pp. 150-157
-
-
Jang, G.R.1
Benet, L.Z.2
-
81
-
-
2442649042
-
Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases
-
Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004; 32: 587-94.
-
(2004)
Drug Metab Dispos
, vol.32
, pp. 587-594
-
-
Sridar, C.1
Goosen, T.C.2
Kent, U.M.3
Williams, J.A.4
Hollenberg, P.F.5
-
82
-
-
0031790709
-
Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir
-
Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998; 26: 552-61.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 552-561
-
-
Koudriakova, T.1
Iatsimirskaia, E.2
Utkin, I.3
Gangl, E.4
Vouros, P.5
Storozhuk, E.6
-
83
-
-
0031900568
-
-
Cato Ard, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. Clin Pharmacol Ther 1998; 63: 414-21.
-
(1998)
Clin Pharmacol Ther
, vol.63
, pp. 414-421
-
-
Ard, C.1
Cavanaugh, J.2
Shi, H.3
Hsu, A.4
Leonard, J.5
Granneman, R.6
-
84
-
-
0031751330
-
Cinical pharmacokinetics and interactions with other anti-HIV agents
-
Hsu A, Granneman GR, Bertz RJ. Cinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
-
(1998)
Clin Pharmacokinet
, vol.35
, pp. 275-291
-
-
Hsu, A.1
Granneman, G.R.2
Bertz, R.J.3
-
85
-
-
7144257182
-
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
-
Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453-64.
-
(1998)
Clin Pharmacol Ther
, vol.63
, pp. 453-464
-
-
Hsu, A.1
Granneman, G.R.2
Cao, G.3
Carothers, L.4
el-Shourbagy, T.5
Baroldi, P.6
-
86
-
-
0031785117
-
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
-
Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 2784-91.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 2784-2791
-
-
Hsu, A.1
Granneman, G.R.2
Cao, G.3
Carothers, L.4
Japour, A.5
El-Shourbagy, T.6
-
87
-
-
0032537990
-
-
Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. J Natl Cancer Inst 1998; 90: 1371-88.
-
(1998)
J Natl Cancer Inst
, vol.90
, pp. 1371-1388
-
-
Fisher, B.1
Constantino, J.P.2
Wickerham, D.L.3
Redmond, C.K.4
Kavanah, M.5
Cronin, W.M.6
-
90
-
-
0036232065
-
The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and down-regulators
-
O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and down-regulators. Lancet Oncol 2002; 3: 207-14.
-
(2002)
Lancet Oncol
, vol.3
, pp. 207-214
-
-
O'Regan, R.M.1
Jordan, V.C.2
-
92
-
-
0028208456
-
Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
-
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 527-537
-
-
Fisher, B.1
Costantino, J.P.2
Redmond, C.K.3
Fisher, E.R.4
Wickerham, D.L.5
Cronin, W.M.6
-
93
-
-
0019411776
-
Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues
-
Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 1981; 256: 859-68.
-
(1981)
J Biol Chem
, vol.256
, pp. 859-868
-
-
Borgna, J.L.1
Rochefort, H.2
-
94
-
-
0036793163
-
Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites
-
Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32: 863-78.
-
(2002)
Xenobiotica
, vol.32
, pp. 863-878
-
-
Zhao, X.J.1
Jones, D.R.2
Wang, Y.H.3
Grimm, S.W.4
Hall, S.D.5
-
95
-
-
0024507146
-
Tamoxifen-warfarin interaction: The Aberdeen hospitals drug file
-
Ritchie LD, Grant SM. Tamoxifen-warfarin interaction: The Aberdeen hospitals drug file. BMJ 1989; 298: 1253.
-
(1989)
BMJ
, vol.298
, pp. 1253
-
-
Ritchie, L.D.1
Grant, S.M.2
-
96
-
-
0024507312
-
Life threatening interaction between tamoxifen and warfarin
-
Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ 1989; 298: 93.
-
(1989)
BMJ
, vol.298
, pp. 93
-
-
Tenni, P.1
Lalich, D.L.2
Byrne, M.J.3
-
97
-
-
84970843754
-
Life threatening interaction between tamoxifen and warfarin
-
Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. Br Med J (Clin Res Ed) 1987; 295: 1141.
-
(1987)
Br Med J (Clin Res Ed)
, vol.295
, pp. 1141
-
-
Lodwick, R.1
McConkey, B.2
Brown, A.M.3
-
98
-
-
0033787393
-
-
Komatsu T, Yamazaki H, Asahi S, Gillam EMJ, Guengerich FP, Nakajima M, et al. Drug Metab Dispos 2000; 28: 1361-8.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 1361-1368
-
-
Komatsu, T.1
Yamazaki, H.2
Asahi, S.3
Gillam, E.M.J.4
Guengerich, F.P.5
Nakajima, M.6
-
99
-
-
0027399545
-
Acetaminophen hepatotoxicity: Potentiation by isoniazid
-
Crippin JS. Acetaminophen hepatotoxicity: Potentiation by isoniazid. Am J Gastroenterol 1993; 88: 590-5.
-
(1993)
Am J Gastroenterol
, vol.88
, pp. 590-595
-
-
Crippin, J.S.1
-
100
-
-
0027958433
-
Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis
-
Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105: 408-11.
-
(1994)
Chest
, vol.105
, pp. 408-411
-
-
Nolan, C.M.1
Sandblom, R.E.2
Thummel, K.E.3
Slattery, J.T.4
Nelson, S.D.5
-
102
-
-
36549059303
-
Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring
-
Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
-
(2007)
Ther Drug Monit
, vol.29
, pp. 687-710
-
-
Zhou, S.F.1
Xue, C.C.2
Yu, X.Q.3
Li, C.4
Wang, G.5
-
103
-
-
0036239016
-
-
Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Pharmacotherapy 2002; 22: 551-6.
-
(2002)
Pharmacotherapy
, vol.22
, pp. 551-556
-
-
Piscitelli, S.C.1
Formentini, E.2
Burstein, A.H.3
Alfaro, R.4
Jagannatha, S.5
Falloon, J.6
-
104
-
-
0031777718
-
Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data an metabolism, together with binding and transport
-
Ito K, Iwatsubo T, Kanamitsu S, Nukajima Y, Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data an metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998; 38: 461-99.
-
(1998)
Annu Rev Pharmacol Toxicol
, vol.38
, pp. 461-499
-
-
Ito, K.1
Iwatsubo, T.2
Kanamitsu, S.3
Nukajima, Y.4
Sugiyama, Y.5
-
105
-
-
0031723235
-
Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver
-
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-411
-
(1998)
Pharmacol Rev
, vol.50
, pp. 387-411
-
-
Ito, K.1
Iwatsubo, T.2
Kanamitsu, S.3
Ueda, K.4
Suzuki, H.5
Sugiyama, Y.6
-
106
-
-
0035064595
-
Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data
-
Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, et al. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab Dispos 2001; 29: 443-52.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 443-452
-
-
Yamano, K.1
Yamamoto, K.2
Katashima, M.3
Kotaki, H.4
Takedomi, S.5
Matsuo, H.6
-
107
-
-
0020575075
-
-
Larry D, Funk-Brentano C, Breil P, Vitaux J, Theodore C, Babany G, et al. Biochem Pharmacol 1983; 32: 1063-8.
-
(1983)
Biochem Pharmacol
, vol.32
, pp. 1063-1068
-
-
Larry, D.1
Funk-Brentano, C.2
Breil, P.3
Vitaux, J.4
Theodore, C.5
Babany, G.6
-
108
-
-
0027483266
-
Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats
-
Ohmori S, Ishii I, Kuriya S, Taniguchi T, Rikihisa T, Hirose S, et al. Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metab Dispos 1993; 21: 358-63.
-
(1993)
Drug Metab Dispos
, vol.21
, pp. 358-363
-
-
Ohmori, S.1
Ishii, I.2
Kuriya, S.3
Taniguchi, T.4
Rikihisa, T.5
Hirose, S.6
-
109
-
-
0031848620
-
(R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6
-
Khojasteh-Bakht SC, Koenigs LL, Peter RM, Trager WF, Nelson SD. (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab Dispos 1998; 26: 701-4.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 701-704
-
-
Khojasteh-Bakht, S.C.1
Koenigs, L.L.2
Peter, R.M.3
Trager, W.F.4
Nelson, S.D.5
-
110
-
-
0032927983
-
The effects of antirhino- and enteroviral vinylacetylene benzimidazoles on cytochrome P450 function and hepatic porphyrin levels in mice
-
Tebbe MJ, Jensen CB, Spitzer WA, Franklin RB, George MC, Phillips DL. The effects of antirhino- and enteroviral vinylacetylene benzimidazoles on cytochrome P450 function and hepatic porphyrin levels in mice. Antiviral Res 1999; 42: 25-33.
-
(1999)
Antiviral Res
, vol.42
, pp. 25-33
-
-
Tebbe, M.J.1
Jensen, C.B.2
Spitzer, W.A.3
Franklin, R.B.4
George, M.C.5
Phillips, D.L.6
-
111
-
-
0018937071
-
Self-catalyzed inactivation of hepatic cytochrorne P-450 by ethynyl substrates
-
Ortiz de Montellano PR, Kunze KL. Self-catalyzed inactivation of hepatic cytochrorne P-450 by ethynyl substrates. J Biol Chem 1980; 255: 5578-85.
-
(1980)
J Biol Chem
, vol.255
, pp. 5578-5585
-
-
Ortiz de Montellano, P.R.1
Kunze, K.L.2
-
112
-
-
0021345344
-
Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids
-
Ortiz de Montellano PR, Reich NO. Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. J Biol Chem 1994; 259: 4136-41.
-
(1994)
J Biol Chem
, vol.259
, pp. 4136-4141
-
-
Ortiz de Montellano, P.R.1
Reich, N.O.2
-
113
-
-
0031717972
-
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein
-
Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: Role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998; 42: S44-9.
-
(1998)
Cancer Chemother Pharmacol
, vol.42
-
-
Sugiyama, Y.1
Kato, Y.2
Chu, X.3
-
114
-
-
0032988933
-
Active efflux of CPT-11 and its metabolites in human KB-derived cell lines
-
Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 1999; 298: 735-41.
-
(1999)
J Pharmacol Exp Ther
, vol.298
, pp. 735-741
-
-
Chu, X.Y.1
Suzuki, H.2
Ueda, K.3
Kato, Y.4
Akiyama, S.5
Sugiyama, Y.6
-
115
-
-
0032533498
-
-
Chu XY, Kato Y, Ueda K, Susuki H, Niinuma K, Tyson CA, et al. Cancer Res 1998; 58: 5137-43.
-
(1998)
Cancer Res
, vol.58
, pp. 5137-5143
-
-
Chu, X.Y.1
Kato, Y.2
Ueda, K.3
Susuki, H.4
Niinuma, K.5
Tyson, C.A.6
-
116
-
-
0030959378
-
Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats
-
Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 1997; 281: 304-14.
-
(1997)
J Pharmacol Exp Ther
, vol.281
, pp. 304-314
-
-
Chu, X.Y.1
Kato, Y.2
Niinuma, K.3
Sudo, K.I.4
Hakusui, H.5
Sugiyama, Y.6
-
117
-
-
0037032045
-
The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1)
-
Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS 2002; 16: 1743-7.
-
(2002)
AIDS
, vol.16
, pp. 1743-1747
-
-
Olson, D.P.1
Scadden, D.T.2
D'Aquila, R.T.3
De Pasquale, M.P.4
-
119
-
-
0032900953
-
Biochemical, cellular, and pharmacological aspects of the multidrug transporter
-
Ambudkar SV, Dey S, Hrycyha CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-98.
-
(1999)
Annu Rev Pharmacol Toxicol
, vol.39
, pp. 361-398
-
-
Ambudkar, S.V.1
Dey, S.2
Hrycyha, C.A.3
Ramachandra, M.4
Pastan, I.5
Gottesman, M.M.6
-
120
-
-
0037229942
-
Role of P-glycoprotein in pharmacokinetics: Clinical implications
-
Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 2003; 41: 59-98.
-
(2003)
Clin Pharmacokinet
, vol.41
, pp. 59-98
-
-
Lin, J.H.1
Yamazaki, M.2
-
121
-
-
0028028123
-
The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function
-
Lecureur V, Fardel O, Guilouzo A. The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett 1994; 355: 187-91.
-
(1994)
FEBS Lett
, vol.355
, pp. 187-191
-
-
Lecureur, V.1
Fardel, O.2
Guilouzo, A.3
-
124
-
-
0024428724
-
Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides
-
Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989; 250: 746-51.
-
(1989)
J Pharmacol Exp Ther
, vol.250
, pp. 746-751
-
-
Tinel, M.1
Descatoire, V.2
Larrey, D.3
Loeper, J.4
Labbe, G.5
Letteron, P.6
-
125
-
-
0034634252
-
Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4
-
Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000; 67: 3103-12.
-
(2000)
Life Sci
, vol.67
, pp. 3103-3112
-
-
Chan, W.K.1
Delucchi, A.B.2
-
126
-
-
0034089555
-
Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4
-
Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res 2000; 17: 419-26.
-
(2000)
Pharm Res
, vol.17
, pp. 419-426
-
-
Kanamitsu, S.1
Ito, K.2
Green, C.E.3
Tyson, C.A.4
Shimada, N.5
Sugiyama, Y.6
-
128
-
-
0020665350
-
Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione
-
Pessayre D, Tinel M, Larrey D, Cobert B, Funck-Brentano C, Babany G. Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J Pharmacol Exp Ther 1983; 224: 695-91.
-
(1983)
J Pharmacol Exp Ther
, vol.224
, pp. 695-791
-
-
Pessayre, D.1
Tinel, M.2
Larrey, D.3
Cobert, B.4
Funck-Brentano, C.5
Babany, G.6
-
129
-
-
0024422358
-
Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics
-
Miura T, Iwasaki M, Komori M, Ohi H, Kitada M, Mitsui H, et al. Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics. J Antimicrob Chemother 1989; 24: 551-9.
-
(1989)
J Antimicrob Chemother
, vol.24
, pp. 551-559
-
-
Miura, T.1
Iwasaki, M.2
Komori, M.3
Ohi, H.4
Kitada, M.5
Mitsui, H.6
-
130
-
-
0036207927
-
Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytorhrome P450 enzymes
-
Hanioka N, Ozawa S, Jinno H, Tanaka-Kagawa T, Nishimura T, Ando M, et al. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytorhrome P450 enzymes. Drug Metab Dispos 2002; 30: 391-6.
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 391-396
-
-
Hanioka, N.1
Ozawa, S.2
Jinno, H.3
Tanaka-Kagawa, T.4
Nishimura, T.5
Ando, M.6
-
131
-
-
11844283327
-
Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism based
-
Richter T, Schwab M, Eichelbaum M, Zanger UM. Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism based. Biochem Pharmacol 2005; 69: 517-24.
-
(2005)
Biochem Pharmacol
, vol.69
, pp. 517-524
-
-
Richter, T.1
Schwab, M.2
Eichelbaum, M.3
Zanger, U.M.4
-
132
-
-
0034954153
-
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thio-TEPA and the autoinduction of cyclophosphamide
-
Huitema AD, Mathot RA, Tibben-MM, Rodenhuis S, Beijnen JH. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thio-TEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn 2001; 28: 211-30.
-
(2001)
J Pharmacokinet Pharmacodyn
, vol.28
, pp. 211-230
-
-
Huitema, A.D.1
Mathot, R.A.2
MM, T.3
Rodenhuis, S.4
Beijnen, J.H.5
-
133
-
-
0033948964
-
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: Comparison with ketoconazole
-
von Moltke LL, Durol AL, Duan SX, Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000; 56: 259-61.
-
(2000)
Eur J Clin Pharmacol
, vol.56
, pp. 259-261
-
-
von Moltke, L.L.1
Durol, A.L.2
Duan, S.X.3
Greenblatt, D.J.4
-
134
-
-
10744229689
-
Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative
-
Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, et al. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos 2003; 31: 1170-5.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 1170-1175
-
-
Luo, G.1
Lin, J.2
Fiske, W.D.3
Dai, R.4
Yang, T.J.5
Kim, S.6
-
135
-
-
0029553030
-
Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor
-
Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 1995; 275: 1527-34.
-
(1995)
J Pharmacol Exp Ther
, vol.275
, pp. 1527-1534
-
-
Chiba, M.1
Nishime, J.A.2
Lin, J.H.3
-
137
-
-
0032706108
-
Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes
-
Masubuchi Y, Horie T. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol 1999; 12: 1028-32.
-
(1999)
Chem Res Toxicol
, vol.12
, pp. 1028-1032
-
-
Masubuchi, Y.1
Horie, T.2
-
138
-
-
0034854303
-
Inhibitory effects of verapamil and diltiazem on siravastatin metabolism in human liver microsomes
-
Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on siravastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51: 461-70.
-
(2001)
Br J Clin Pharmacol
, vol.51
, pp. 461-470
-
-
Yeo, K.R.1
Yeo, W.W.2
-
139
-
-
0032773854
-
Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation
-
Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 1999; 290: 1116-25.
-
(1999)
J Pharmacol Exp Ther
, vol.290
, pp. 1116-1125
-
-
Jones, D.R.1
Gorski, J.C.2
Hamman, M.A.3
Mayhew, B.S.4
Rider, S.5
Hall, S.D.6
-
140
-
-
0033959578
-
Drug interactions with calcium channel blockers: Possible-involvement of metabolite-intermediate complexation with CYP3A
-
Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: Possible-involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28: 125-30.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 125-130
-
-
Ma, B.1
Prueksaritanont, T.2
Lin, J.H.3
-
141
-
-
17844387084
-
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil
-
Wang YH, Jones DR, Hall SD. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 2005; 33: 664-71.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 664-671
-
-
Wang, Y.H.1
Jones, D.R.2
Hall, S.D.3
-
142
-
-
0025184340
-
Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene
-
Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990; 3: 363-71.
-
(1990)
Chem Res Toxicol
, vol.3
, pp. 363-371
-
-
Guengerich, F.P.1
-
143
-
-
0035996330
-
Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation
-
Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, et al. Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 2002; 15: 907-14.
-
(2002)
Chem Res Toxicol
, vol.15
, pp. 907-914
-
-
Chen, Q.1
Ngui, J.S.2
Doss, G.A.3
Wang, R.W.4
Cai, X.5
DiNinno, F.P.6
-
144
-
-
0032865554
-
Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components
-
Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999; 48: 543-52.
-
(1999)
Br J Clin Pharmacol
, vol.48
, pp. 543-552
-
-
Eagling, V.A.1
Profit, L.2
Back, D.J.3
-
145
-
-
14644439295
-
Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: Mechanism-based inhibition
-
Usia T, Watabe T, Kadota S, Tezuka Y. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci 2005; 76: 2381-91.
-
(2005)
Life Sci
, vol.76
, pp. 2381-2391
-
-
Usia, T.1
Watabe, T.2
Kadota, S.3
Tezuka, Y.4
-
146
-
-
0030696487
-
Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
-
Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-33.
-
(1997)
Drug Metab Dispos
, vol.25
, pp. 1228-1233
-
-
Schmiedlin-Ren, P.1
Edwards, D.J.2
Fitzsimmons, M.E.3
He, K.4
Lown, K.S.5
Woster, P.M.6
-
147
-
-
24144432308
-
Mechanism-based inactivation of human liver microsomal CYP3A4 by rutae-carpine and limonin from Evodia fruit extract
-
Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutae-carpine and limonin from Evodia fruit extract. Drug Metab Pharmacokinet 2005; 20: 34-45.
-
(2005)
Drug Metab Pharmacokinet
, vol.20
, pp. 34-45
-
-
Iwata, H.1
Tezuka, Y.2
Kadota, S.3
Hiratsuka, A.4
Watabe, T.5
-
148
-
-
0034889873
-
Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein
-
Stupans I, Murray M, Kirlich A, Tuck KL, Hayball PJ. Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food Chem Toxicol 2001; 39: 1119-24.
-
(2001)
Food Chem Toxicol
, vol.39
, pp. 1119-1124
-
-
Stupans, I.1
Murray, M.2
Kirlich, A.3
Tuck, K.L.4
Hayball, P.J.5
-
149
-
-
0036785511
-
Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine
-
Masubuchi Y, Ose A, Horie T. Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab Dispos 2002; 30: 1143-8
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 1143-1148
-
-
Masubuchi, Y.1
Ose, A.2
Horie, T.3
-
150
-
-
0142181023
-
Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components
-
Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003; 31: 1391-7
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 1391-1397
-
-
Chatterjee, P.1
Franklin, M.R.2
-
151
-
-
1342310586
-
Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol
-
Alvarez-Diez TM, Zheng J. Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol. Chem Res Toxicol 2004; 17: 150-7.
-
(2004)
Chem Res Toxicol
, vol.17
, pp. 150-157
-
-
Alvarez-Diez, T.M.1
Zheng, J.2
-
152
-
-
0033791657
-
In vitro evaluation of the disposition of A novel cysteine protease inhibitor
-
Jacobsen W, Christians U, Benet LZ. In vitro evaluation of the disposition of A novel cysteine protease inhibitor. Drug Metab Dispos 2000; 28: 1343-51.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 1343-1351
-
-
Jacobsen, W.1
Christians, U.2
Benet, L.Z.3
-
153
-
-
0037300346
-
A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate
-
Zdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, et al. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. Eur J Clin Pharmacol 2003; 58: 683-8.
-
(2003)
Eur J Clin Pharmacol
, vol.58
, pp. 683-688
-
-
Zdravkovic, M.1
Olsen, A.K.2
Christiansen, T.3
Schulz, R.4
Taub, M.E.5
Thomsen, M.S.6
-
154
-
-
33744975050
-
Thienopyridines and statins: Assessing a potential drug-drug interaction
-
Neubauer H, Mugge A. Thienopyridines and statins: Assessing a potential drug-drug interaction. Curr Pharm Des 2006; 12(10): 1271-80.
-
(2006)
Curr Pharm Des
, vol.12
, Issue.10
, pp. 1271-1280
-
-
Neubauer, H.1
Mugge, A.2
-
155
-
-
33745002984
-
Porcine cytochrome P450 and metabolism
-
Skaanild MT. Porcine cytochrome P450 and metabolism. Curr Pharm Des 2006; 12(11): 1421-7.
-
(2006)
Curr Pharm Des
, vol.12
, Issue.11
, pp. 1421-1427
-
-
Skaanild, M.T.1
-
156
-
-
33748745120
-
Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles
-
Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des 2006; 12(27): 3459-65.
-
(2006)
Curr Pharm Des
, vol.12
, Issue.27
, pp. 3459-3465
-
-
Supuran, C.T.1
Mastrolorenzo, A.2
Barbaro, G.3
Scozzafava, A.4
|